This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lux, M. L. Articles by Fletcher, J. A. Search for Related Content PubMed PubMed Citation Articles by Lux, M. L. Articles by Fletcher, J. A.

(American Journal of Pathology. 2000;156:791-795.)
© 2000 American Society for Investigative Pathology

Short Communications

KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors

Marcia L. Lux^*, Brian P. Rubin^*, Tara L. Biase^*, Chang-Jie Chen^*, Timothy Maclure^*, George Demetri, Sheng Xiao^*, Samuel Singer^§, Christopher D.M. Fletcher^* and Jonathan A. Fletcher^*

From the Departments of Pathology^*
and Surgery,
Brigham and Women’s Hospital; the Department of Pediatric Oncology,
Dana-Farber Cancer Institute and Children’s Hospital; and the Departments of Pathology,^*
Surgery,^§
and Pediatrics,
Harvard Medical School, Boston, Massachusetts

	Abstract

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms arising in the gastrointestinal tract. GISTs express the KIT receptor tyrosine kinase, and many cases have activating mutations in the KIT juxtamembrane region. We now report an analysis of KIT cDNA and genomic sequences in eight GISTs that lack juxtamembrane region mutations. Six cases contained heterozygous exon 9 mutations in which six nucleotides, encoding Ala-Tyr, were duplicated. The other two cases contained homozygous exon 13 missense mutations, resulting in substitution of Glu for Lys⁶⁴², that were associated with constitutive KIT tyrosine phosphorylation. Sequence analysis of DNAs from nonneoplastic companion tissues revealed that both the exon 9 and exon 13 mutations were somatic. These are the first descriptions, in any tumor, of mutations in KIT exons encoding the C-terminal end of the extracellular domain and the first part of the split kinase domain. These findings indicate that KIT may be activated by mutations in at least three domains—extracellular, juxtamembrane, and kinase—in GISTs.

	Introduction

Top Abstract Introduction Materials and Methods Results and Discussion References

	Materials and Methods

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Patient Samples

The study group consisted of eight primary intraabdominal neoplasms (one gastric, five small bowel, one mesenteric, one abdominal wall) biopsied at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. All cases were evaluated histologically by two of the authors (BPR and CDMF) and were diffusely and strongly immunoreactive with KIT antibody (A-4052, rabbit polyclonal antiserum, 1:100; DAKO Corporation, Carpinteria, CA), according to analysis by an avidin-biotin-peroxidase complex method after microwave antigen retrieval. All cases lacked mutations of KIT exons 10 and 11, a region containing the entire coding sequence for the KIT juxtamembrane domain, as determined by sequencing of genomic DNAs isolated from frozen tumor materials.

RT-PCR Analysis of KIT Transcripts

RNAs were isolated from frozen tissue, using TRIzol (GIBCO BRL Life Technologies, Gaithersburg, MD), and cDNAs were synthesized using AMV reverse transcriptase and random 9-mer primers (TaKaRa Shuzo Co., Seoul, Korea), according to the manufacturer’s protocols. Polymerase chain reaction (PCR) amplifications were performed using Taq DNA polymerase and oligonucleotide primer sequences as described by Furitsu et al.⁶ DNAs were amplified in 20-µl PCR reactions of 0.5 minute at 94°C, 0.5 minute at 60°C, and 1 minute at 72°C for 35 cycles. Amplified products were purified with the QIAquick gel extraction kit (Qiagen, Valencia, CA) and directly sequenced in the forward and reverse directions with ABI BigDye terminators (Applied Biosystems, Foster City, CA). Sequences were analyzed on an ABI Prism 377 sequencer (Applied Biosystems), and alignments and mutation scanning were performed using Sequence Navigator (Applied Biosystems) and BLAST (National Center for Biotechnology Information) software.

Genomic DNA Sequencing

DNAs were isolated from frozen GIST specimens by the use of NaOH boiling preps. DNAs were isolated from paraffin sections of nonneoplastic companion tissues (evaluated to exclude the possibility of constitutional polymorphisms), using standard proteinase K digestion methods. Intronic primers were chosen using the Whitehead Genome Center Primer3 software, and all intronic primers were numbered according to KIT genomic sequence Genbank number U63834. The PCR cycling conditions were identical to those in the cDNA amplifications.

Exon 9: F/KIT/74056, 5'-ATTTATTTTCCTAGAGTAAGCCAGGG-3' R/KIT/74360, 5'-ATCATGACTGATATGGTAGACAGAGC-3'

Exons 12–13: F/KIT/75961, 5'-ATTTTGAAACTGCACAAATGGTCCTT-3' R/KIT/76499, 5'-GCAAGAGAGAACAACAGTCTGGGTAA-3'

The PCR products were purified, as described above, and cycle sequencing was performed using the following intronic primer pairs:

Exon 9: Same as for PCR

Exons 12–13: F/KIT/76032, 5'-CACCATCACCACTTACTTGTTGTCT-3' R/KIT/76403, 5'-GACAGACAATAAAAGGCAGCTTGGAC-3'

Fluorescence in Situ Hybridization

Total yeast DNA was isolated from CEPH yeast artificial chromosome clone, 840_E_11, containing the human KIT locus at chromosome band 4q12. Two hundred nanograms of 840_E_11 DNA was biotin labeled by random-octamer priming (BioPrime Kit; Gibco, Rockville, MD), and 500 ng of the labeled YAC was cohybridized with a digoxigenin-labeled chromosome 4 pericentromeric probe (D4Z1) against cytogenetic preparations of GIST cells. YAC and centromere probe detection was carried out with strepavidin-FITC (Zymed Laboratories, South San Francisco, CA) and rhodamine anti-digoxigenin (Zymed Laboratories), respectively.

Evaluation of KIT Tyrosine Phosphorylation

GIST and malignant peripheral nerve sheath tumor (MPNST) cells were lysed in ice-cold 1% NP-40, 50 mmol/L Tris (pH 8.0), 100 mmol/L sodium fluoride, 30 mmol/L sodium pyrophosphate, 2 mmol/L sodium molybdate, 5 mmol/L EDTA, 2 mmol/L sodium vanadate, 5 µg/ml aprotinin, 5 µg/ml leupeptin, and 50 µg/ml phenylmethylsulfonyl fluoride (lysis buffer). Lysates were incubated with anti-KIT (C-19; Santa Cruz) for 2 hours, followed by 20 µl of protein A-Sepharose (Zymed Laboratories) for 1 hour at 4°C. Immunoprecipitates were washed three times in lysis buffer, then eluted at 100°C into 40 µl of sodium dodecyl sulfate-polyacrylamide gel electrophores (SDS-PAGE) loading buffer and resolved by SDS-PAGE under reducing conditions (4–12% gradient gels). Immunoblotting was accomplished by electrophoretic transfer to polyvinyl pyrrolidine fluoride membranes (Millipore), blocking in phosphate-buffered saline containing 0.2% Tween-20 and 5% dry milk for 1 hour, then sequential incubation with murine anti-phosphotyrosine (PY99; Santa Cruz) and horseradish peroxidase anti-mouse Ig (Amersham, Piscataway, NJ). Detection was made by chemoluminescence (SuperSignal West Femto Maximum Sensitivity Substrate; Pierce, Rockford, IL).

	Results and Discussion

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Initial mutation screening was carried out by sequence analysis of the entire KIT coding sequence, and potential mutations were then confirmed by genomic sequencing. Each of the eight GISTs contained a single mutation. Six cases had heterozygous exon 9 mutations (1530ins6) in which six nucleotides were duplicated (Figure 1A) . In one of these cases, the 1530ins6 mutation was demonstrated both in the primary tumor and in a subsequently biopsied metastasis. cDNA and genomic sequencing indicated a 50:50 ratio, for wild-type:mutant transcripts and alleles, respectively, in the 1530ins6 mutation cases (Figure 1A) . These findings suggest that transcriptional regulation of the mutant 1530ins6 allele is unperturbed, compared to that of the nonmutant allele. In contrast, the remaining two GISTs contained homozygous exon 13 missense mutations, 1945A>G. Wildtype KIT genomic and cDNA sequences were undetectable in both of these cases (Figure 1B) , and loss of KIT allelic heterozygosity was evidenced by loss of constitutional polymorphisms in exon 10, intron 16, and intron 17 (case 7) and in exon 10 and intron 17 (case 8). Dual-color fluorescence in situ hybridization, using a KIT-containing YAC clone, showed no evidence of KIT deletion, or other rearrangement, in either copy of chromosome 4 from the GISTs with exon 13 mutations (Figure 1C) . Together, these data demonstrate loss of the wild-type KIT allele and are consistent with duplication of the 1945A>G mutant allele.

View larger version (25K): [in this window] [in a new window]   Figure 1. Genomic evaluations of KIT by sequencing (A and B) and fluorescence in situ hybridization (C). A: Sequence analysis of total genomic DNA demonstrates a heterozygous exon 9 6-bp insertion/duplication in a GIST (top). Sequence analysis of cloned PCR products, from the same GIST as shown at top, demonstrates the wild-type (middle) and mutant (bottom) alleles. B: Sequence analysis of total genomic DNA demonstrates a homozygous exon 13 A>G missense mutation. The GIST sequence is at bottom, and the wild-type sequence, obtained from adjacent nonneoplastic tissue, is at top. C: Fluorescence in situ hybridization demonstrates nondeleted KIT, in the same GIST as in B, consistent with loss of the chromosome 4 homolog containing the wild-type KIT allele and duplication of the chromosome 4 homolog containing the mutant KIT allele. FITC signals (green) identify the KIT loci at chromosome band 4q12, and rhodamine signals (red) identify the chromosome 4 pericentromeric region.

Most GISTs are characterized by diffuse KIT protein expression, and many GISTs contain oncogenic KIT mutations.¹² To date, GIST KIT mutations have been reported only in the exon 11 juxtamembrane domain.^12-17 Oncogenic KIT exon 11 mutations are associated with constitutive ligand-independent receptor dimerization and activation of the kinase domain.^9,12 Although KIT exon 11 juxtamembrane domain mutations are found in most GISTs, a subset of cases lack such mutations. In our experience (B. P. Rubin and J. A. Fletcher, unpublished data) 32 of 45 GISTs expressed KIT (as determined immunohistochemically) and contained exon 11 mutations. The remaining 13 cases expressed KIT but lacked exon 11 mutations. We now report that eight of these 13 GISTs contain somatic mutations in KIT exon 9 (extracellular domain) or exon 13 (first part of the split tyrosine kinase domain). Clinicopathological correlations, for the entire series, will be reported separately.

Although KIT exon 9 mutations have not been described previously, it is likely that the 1530ins6 mutations activate the receptor via ligand-independent oligomerization. Extracellular region mutations have been characterized in several other receptor tyrosine kinase genes, including FGFR2, FGFR3, and RET, and in all cases these mutations are associated with constitutive receptor oligomerization.^18-21 Although the mechanistic implications of the novel exon 13 (1945A>G) mutations are unclear, it is worth noting that Lys⁶⁴² is conserved in all members of the type III RTK family, highlighting its likely functional importance. KIT is constitutively tyrosine-phosphorylated, in a ligand-independent manner, in a cell line established from one of our exon 13 mutant (1945A>G) GISTs (Figure 2) . Therefore, the exon 13 mutation is almost certainly activating. The Lys⁶⁴²Glu (K642E) substitution imparts a negative charge and would likely alter the three-dimensional structure of the mutant protein. This potential conformational change might either encourage receptor oligomerization or, alternatively, might be associated with constitutive kinase activation in the absence of receptor oligomerization.²² It is intriguing that wild-type KIT sequences were undetectable in either of the two GISTs with exon 13 mutations. This finding is notable, because heterodimerization—i.e., interaction between mutant and nonmutant receptors—is a potential activating mechanism for receptor tyrosine kinase oncoproteins. The homozygous nature of the K642E mutations demonstrates that heterodimerization is not requisite, in vivo, for oncogenic activation. It is conceivable that heterodimerization blunts the activating impact of the K642E mutation, thereby providing selective advantage to cells in which the wild-type allele has been deleted. Alternatively, this mutation might be intrinsically less activating than the generally heterozygous mutations found in exons 9 and 11. GIST precursors might require two copies of the mutant allele (loss of the wild-type allele followed by duplication of the mutant) for neoplastic transformation.

View larger version (71K): [in this window] [in a new window]   Figure 2. Demonstration of high-level, ligand-independent, KIT tyrosine phosphorylation in a GIST cell line, established from case 7, expressing the KIT K642E oncoprotein. Immunoprecipitations and Western blotting were with KIT and phosphotyrosine antibodies, respectively. K642E mutant KIT is tyrosine phosphorylated in GIST cells cultured in 15% fetal bovine serum (second lane), serum-free media with stem cell factor 100 ng/ml (third lane), and serum-free media without stem cell factor (fourth lane). Low-level KIT activation, in a malignant peripheral nerve sheath tumor cell line (ST88-14),25,26 is not detected on this 10-second film exposure (first lane).

	Footnotes

 
Address reprint requests to Dr. Brian P. Rubin or Dr. Jonathan A. Fletcher, Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. E-mail: bprubin{at}bics.bwh.harvard.edu

Drs. Lux and Rubin contributed equally to this work.

Accepted for publication November 16, 1999.

	References

Top Abstract Introduction Materials and Methods Results and Discussion References

 

1. Fleischman RA: From white spots to stem cells: the role of the Kit receptor in mammalian development. Trends Genet 1993, 9:285-290[Medline]
2. Russell ES: Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979, 20:357-459[Medline]
3. Kitamura Y, Go S: Decreased production of mast cells in S1/S1d anemic mice. Blood 1979, 53:492-497[Free Full Text]
4. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A: W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373:347-349[Medline]
5. Isozaki K, Hirota S, Nakama A, Miyagawa J, Shinomura Y, Xu Z, Nomura S, Kitamura Y: Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995, 109:456-464[Medline]
6. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993, 92:1736-1744
7. Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994, 83:2619-2626[Abstract/Free Full Text]
8. Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995, 106:377-385[Medline]
9. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y: Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 1996, 87:273-283[Abstract/Free Full Text]
10. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, Kuramoto A, Satow Y: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995, 91:661-663[Medline]
11. Tian Q, Frierson HF, Jr, Krystal GW, Moskaluk CA: Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999, 154:1643-1647[Abstract/Free Full Text]
12. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580
13. Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M, Nishida T, Kanayama S, Kitamura Y, Shinomura Y, Matsuzawa Y: A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998, 115:1090-1095[Medline]
14. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O’Leary TJ: KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998, 78:1633-1636[Medline]
15. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999, 154:53-60[Abstract/Free Full Text]
16. Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF, Jr: Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999, 18:1897-1902[Medline]
17. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59:4297-4300[Abstract/Free Full Text]
18. d’Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ: Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 1998, 9:71-78[Abstract]
19. Bongarzone I, Vigano E, Alberti L, Borrello MG, Pasini B, Greco A, Mondellini P, Smith DP, Ponder BA, Romeo G, Pierotti MA: Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene 1998, 16:2295-2301[Medline]
20. Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, Donoghue DJ: Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc Natl Acad Sci USA 1998, 95:4567-4572[Abstract/Free Full Text]
21. Webster MK, Donoghue DJ: FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997, 13:178-182[Medline]
22. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85:790-798[Abstract/Free Full Text]
23. Kitamura Y, Go S, Hatanaka K: Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978, 52:447-452[Abstract/Free Full Text]
24. Maeda H, Yamagata A, Nishikawa S, Yoshinaga K, Kobayashi S, Nishi K, Nishikawa S: Requirement of c-kit for development of intestinal pacemaker system. Development 1992, 116:369-375[Medline]
25. Ryan JJ, Klein KA, Neuberger TJ, Leftwich JA, Westin EH, Kauma S, Fletcher JA, DeVries GH, Huff TF: Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 1994, 37:415-432[Medline]
26. Badache A, Muja N, De Vries GH: Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 1998, 17:795-800[Medline]

This article has been cited by other articles:

				P. A. Cassier, A. Dufresne, and J.-Y. Blay Controversies in the Adjuvant Treatment of Gastrointestinal Stromal Tumors (GIST) with Imatinib ASCO Educational Book, January 1, 2008; 2008(1): 524 - 528. [Abstract] [Full Text] [PDF]

				C. H. Holdsworth, R. D. Badawi, J. B. Manola, M. F. Kijewski, D. A. Israel, G. D. Demetri, and A. D. Van den Abbeele CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor Am. J. Roentgenol., December 1, 2007; 189(6): W324 - W330. [Abstract] [Full Text] [PDF]

				J. Desai, S. Shankar, M. C. Heinrich, J. A. Fletcher, C. D. Fletcher, J. Manola, J. A. Morgan, C. L. Corless, S. George, K. Tuncali, et al. Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors Clin. Cancer Res., September 15, 2007; 13(18): 5398 - 5405. [Abstract] [Full Text] [PDF]

				L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]

				A. Zamo, A. Bertolaso, I. Franceschetti, G. Weirich, P. Capelli, S. Pecori, M. Chilosi, H. Hoefler, F. Menestrina, and A. Scarpa Microfluidic Deletion/Insertion Analysis for Rapid Screening of KIT and PDGFRA Mutations in CD117-Positive Gastrointestinal Stromal Tumors: Diagnostic Applications and Report of a New KIT Mutation J. Mol. Diagn., April 1, 2007; 9(2): 151 - 157. [Abstract] [Full Text] [PDF]

				J.-Y. Blay, A. Le Cesne, I. Ray-Coquard, B. Bui, F. Duffaud, C. Delbaldo, A. Adenis, P. Viens, M. Rios, E. Bompas, et al. Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group J. Clin. Oncol., March 20, 2007; 25(9): 1107 - 1113. [Abstract] [Full Text] [PDF]

				J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian Somatic Activation of KIT in Distinct Subtypes of Melanoma J. Clin. Oncol., September 10, 2006; 24(26): 4340 - 4346. [Abstract] [Full Text] [PDF]

				L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]

				C. Tarn, Y. V. Skorobogatko, T. Taguchi, B. Eisenberg, M. von Mehren, and A. K. Godwin Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms. Cancer Res., May 15, 2006; 66(10): 5477 - 5486. [Abstract] [Full Text] [PDF]

				R. S. Benjamin, C. D. Blanke, J.-Y. Blay, S. Bonvalot, and B. Eisenberg Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies Oncologist, January 1, 2006; 11(1): 9 - 20. [Abstract] [Full Text] [PDF]

				S. R. McLean, M. Gana-Weisz, B. Hartzoulakis, R. Frow, J. Whelan, D. Selwood, and C. Boshoff Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala Mol. Cancer Ther., December 1, 2005; 4(12): 2008 - 2015. [Abstract] [Full Text] [PDF]

				G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann. Onc., November 1, 2005; 16(11): 1811 - 1816. [Abstract] [Full Text] [PDF]

				F. Haller, B. Gunawan, A. von Heydebreck, S. Schwager, H.-J. Schulten, J. Wolf-Salgo, C. Langer, G. Ramadori, H. Sultmann, and L. Fuzesi Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors Clin. Cancer Res., September 15, 2005; 11(18): 6589 - 6597. [Abstract] [Full Text] [PDF]

				V. Munugalavadla, L. C. Dore, B. L. Tan, L. Hong, M. Vishnu, M. J. Weiss, and R. Kapur Repression of c-Kit and Its Downstream Substrates by GATA-1 Inhibits Cell Proliferation during Erythroid Maturation Mol. Cell. Biol., August 1, 2005; 25(15): 6747 - 6759. [Abstract] [Full Text] [PDF]

				J. D. Growney, J. J. Clark, J. Adelsperger, R. Stone, D. Fabbro, J. D. Griffin, and D. G. Gilliland Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 Blood, July 15, 2005; 106(2): 721 - 724. [Abstract] [Full Text] [PDF]

				M Korja, J Finne, T T Salmi, H Haapasalo, M Tanner, and J Isola No GIST-type c-kit gain of function mutations in neuroblastic tumours J. Clin. Pathol., July 1, 2005; 58(7): 762 - 765. [Abstract] [Full Text] [PDF]

				C. R. Antonescu, P. Besmer, T. Guo, K. Arkun, G. Hom, B. Koryotowski, M. A. Leversha, P. D. Jeffrey, D. Desantis, S. Singer, et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation Clin. Cancer Res., June 1, 2005; 11(11): 4182 - 4190. [Abstract] [Full Text] [PDF]

				F. P. Li, J. A. Fletcher, M. C. Heinrich, J. E. Garber, S. E. Sallan, C. Curiel-Lewandrowski, A. Duensing, M. van de Rijn, L. E. Schnipper, and G. D. Demetri Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred J. Clin. Oncol., April 20, 2005; 23(12): 2735 - 2743. [Abstract] [Full Text] [PDF]

				T. M. Kohl, S. Schnittger, J. W. Ellwart, W. Hiddemann, and K. Spiekermann KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor Blood, April 15, 2005; 105(8): 3319 - 3321. [Abstract] [Full Text] [PDF]

				S. Uccini, O. Mannarino, H. P. McDowell, U. Pauser, R. Vitali, P. G. Natali, P. Altavista, T. Andreano, S. Coco, R. Boldrini, et al. Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors Clin. Cancer Res., January 1, 2005; 11(1): 380 - 389. [Abstract] [Full Text] [PDF]

				M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF]

				H. Choi, C. Charnsangavej, S. d. C. Faria, E. P. Tamm, R. S. Benjamin, M. M. Johnson, H. A. Macapinlac, and D. A. Podoloff CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings Am. J. Roentgenol., December 1, 2004; 183(6): 1619 - 1628. [Abstract] [Full Text] [PDF]

				C. L. Corless, L. McGreevey, A. Town, A. Schroeder, T. Bainbridge, P. Harrell, J. A. Fletcher, and M. C. Heinrich KIT Gene Deletions at the Intron 10-Exon 11 Boundary in GI Stromal Tumors J. Mol. Diagn., November 1, 2004; 6(4): 366 - 370. [Abstract] [Full Text] [PDF]

				S Carvalho, A O e Silva, F Milanezi, S Ricardo, D Leitao, I Amendoeira, and F C Schmitt c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J. Clin. Pathol., October 1, 2004; 57(10): 1075 - 1079. [Abstract] [Full Text] [PDF]

				C. L. Corless, J. A. Fletcher, and M. C. Heinrich Biology of Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825. [Abstract] [Full Text] [PDF]

				J. V. Heymach, J. Desai, J. Manola, D. W. Davis, D. J. McConkey, D. Harmon, D. P. Ryan, G. Goss, T. Quigley, A. D. Van den Abbeele, et al. Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas Clin. Cancer Res., September 1, 2004; 10(17): 5732 - 5740. [Abstract] [Full Text] [PDF]

				L. Boldrini, S. Ursino, S. Gisfredi, P. Faviana, V. Donati, T. Camacci, M. Lucchi, A. Mussi, F. Basolo, R. Pingitore, et al. Expression and Mutational Status of c-kit in Small-Cell Lung Cancer: Prognostic Relevance Clin. Cancer Res., June 15, 2004; 10(12): 4101 - 4108. [Abstract] [Full Text] [PDF]

				C. R. Antonescu, A. Viale, L. Sarran, S. J. Tschernyavsky, M. Gonen, N. H. Segal, R. G. Maki, N. D. Socci, R. P. DeMatteo, and P. Besmer Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site Clin. Cancer Res., May 15, 2004; 10(10): 3282 - 3290. [Abstract] [Full Text] [PDF]

				N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]

				T. Kindler, F. Breitenbuecher, A. Marx, J. Beck, G. Hess, B. Weinkauf, J. Duyster, C. Peschel, C. J. Kirkpatrick, M. Theobald, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia Blood, May 15, 2004; 103(10): 3644 - 3654. [Abstract] [Full Text] [PDF]

				B. L. Eisenberg and I. Judson Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy Ann. Surg. Oncol., May 1, 2004; 11(5): 465 - 475. [Abstract] [Full Text] [PDF]

				T. W. Kim, H. Lee, Y.-K. Kang, M. S. Choe, M.-H. Ryu, H. M. Chang, J. S. Kim, J. H. Yook, B. S. Kim, and J. S. Lee Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors Clin. Cancer Res., May 1, 2004; 10(9): 3076 - 3081. [Abstract] [Full Text] [PDF]

				P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib Blood, April 15, 2004; 103(8): 2929 - 2935. [Abstract] [Full Text] [PDF]

				J. L. Hornick and C. D. M. Fletcher The Significance of KIT (CD117) in Gastrointestinal Stromal Tumors International Journal of Surgical Pathology, April 1, 2004; 12(2): 93 - 97. [PDF]

				J. N. Cormier and R. E. Pollock Soft Tissue Sarcomas CA Cancer J Clin, March 1, 2004; 54(2): 94 - 109. [Abstract] [Full Text] [PDF]

				M. E. Robson, E. Glogowski, G. Sommer, C. R. Antonescu, K. Nafa, R. G. Maki, N. Ellis, P. Besmer, M. Brennan, and K. Offit Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia Clin. Cancer Res., February 15, 2004; 10(4): 1250 - 1254. [Abstract] [Full Text] [PDF]

				I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, C. L. Corless, G. D. Demetri, C. D. Blanke, M. von Mehren, H. Joensuu, L. S. McGreevey, C.-J. Chen, A. D. Van den Abbeele, B. J. Druker, et al. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor J. Clin. Oncol., December 1, 2003; 21(23): 4342 - 4349. [Abstract] [Full Text] [PDF]

				M. C. Heinrich Is KIT an Important Therapeutic Target in Small Cell Lung Cancer?: Commentary re: B. E. Johnson et al., Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin. Cancer Res., 9: 5880-5887, 2003. Clin. Cancer Res., December 1, 2003; 9(16): 5825 - 5828. [Full Text] [PDF]

N. K. Pryer, L. B. Lee, R. Zadovaskaya, X. Yu, J. Sukbuntherng, J. M. Cher